Carclo plc (LSE:CAR) has just hit the two profitability targets it set itself in 2022, ahead of plan, yet the precision-manufacturing group is valued at roughly £26m and its shares touched a 52-week low on the day it published those results. That disconnect is the question hanging over the London Stock Exchange Main Market small-cap as it heads into its Annual General Meeting on 9 September 2026.

Full-year results for the twelve months to 31 March 2026, released on 1 July 2026, showed underlying operating profit up 28% to £12.6m, return on sales of 11.0% and return on Capital employed of 29.1%. Revenue, however, fell 5.8% to £114.2m and net Debt rose. Chief executive Frank Doorenbosch has unveiled a "Precision 2030" growth plan, and the market is waiting to see whether Margin discipline can be converted into top-line expansion.

Full-year results: targets met, Revenue still falling

For the year ended 31 March 2026 (FY26), Carclo reported revenue of £114.2m against £121.2m in FY25, attributing the decline to the deliberate exit of low-margin work and the completion of customer projects. Underlying operating profit rose from £9.8m to £12.6m, statutory operating profit from £7.6m to £12.3m, and profit before tax from £2.7m to £4.8m. Statutory Basic Earnings Per Share were 3.7p (FY25: 1.2p), while underlying EPS slipped to 4.1p from 4.3p.

Both 2022 targets were exceeded: return on sales reached 11.0% (FY25: 8.1%) against a 10% goal, and ROCE 29.1% (FY25: 24.4%) against 25%. Underlying EBITDA rose 13.6% to £18.6m.

Mr Doorenbosch said the "strategy is delivering" and that "the next phase is growth", adding that he was "excited to introduce our Precision 2030 growth plan, which highlights our confidence in our ability to innovate, to win new Business and increase our growth rates." That plan targets organic revenue growth above 8% a year compounded to FY31, net debt below 0.5 times EBITDA, and minimum 10% return on sales and 25% ROCE on new work. Investment priorities include liquid silicone rubber, micro-moulding, the proprietary C-Mould tooling platform, drug-delivery devices, pharmaceutical closures and connected inhalers using Carclo's Syncura software. No Dividend was proposed for FY26; lender approval is required for future distributions.

What Carclo does

Carclo traces its roots to 1924 but today describes itself as a "precision partner in regulated markets", making precision plastic, metal and optical components for life sciences (in vitro diagnostics, medical devices, drug delivery and pharmaceutical packaging), aerospace and defence, and safety and security customers.

Carclo Technical Plastics (CTP) is by far the larger of two divisions, with FY26 revenue of £98.2m (FY25: £107.0m) and operating profit of £15.1m at a 15.4% margin (FY25: 11.6%). Manufacturing Solutions generated £88.5m and the project-driven Design and Engineering unit £9.7m, down 28% as US customer activity slowed. CTP operates from Mitcham in the UK, Pennsylvania in the US, Brno in the Czech Republic, and sites in China and India.

The Speciality division grew revenue 12.5% to £16.0m with operating profit of £3.6m at a 22.4% margin (FY25: 19.7%). It houses the Bruntons aerospace business in Musselburgh, Scotland, which reported a third consecutive year of record orders for flight-control cables, the Jacottet machining Facility in France, and the small Light and Motion optics unit. The top five customers account for about 70% of revenue; the largest relationship, spanning some sixty programmes, was renewed for five years in July 2025.

Cash, debt and the pension

The Balance Sheet is the weaker part of the picture. Net debt (gross debt of £29.7m less cash of £5.8m) rose to £23.9m at 31 March 2026 from just over £19m a year earlier, or 1.3 times underlying EBITDA. Cash generated from operations fell to £12.0m from £19.1m, with cash conversion of 66% against 135% in FY25 after a £6.3m working-capital outflow. Free Cash Flow after £2.8m of Capital Expenditure was £9.2m.

The main drag was the legacy defined-benefit pension scheme. Contributions rose to £8.6m in FY26 from £3.2m, including a one-off £5.1m lump sum in April 2025 agreed under the triennial valuation. The IAS 19 Liability stood at £46.8m at year-end (FY25: £51.8m), and the recovery plan requires £3.5m a year until FY29, then £5.8m indexed annually to FY37. Finance expense of £7.4m, including £3.5m of non-cash items, explains the gap between operating profit and profit before tax.

Funding comes from a £36m asset-backed facility with BZ Commercial Finance agreed in April 2025, comprising a £27.0m term Loan (£24.9m drawn) and an undrawn £9.0m revolver, maturing in April 2028. Directors concluded the going-concern basis was appropriate to June 2027, although a combined severe-downside scenario showed a temporary fixed-charge cover breach that management said it could mitigate.

What could move the shares next

The AGM on 9 September 2026 in Musselburgh offers the first trading commentary since July. Management has guided to positive organic revenue growth in FY27 with trading "weighted towards the second half", so the interim results, due around November if last year's timing holds, will be the first real test of Precision 2030.

Aerospace remains the clearest tailwind, with capacity being expanded at Bruntons and Jacottet after record order intake. In life sciences, a recovery in diagnostics volumes after a "notably weaker respiratory virus season" would restore momentum in the group's largest end-market. Drug-delivery platforms and Syncura-enabled inhalers are longer-dated catalysts. Progress on net debt towards the 0.5 times EBITDA target, or a resumption of dividends once lenders consent, would also be closely watched.

Risks investors should watch

Customer concentration is the most obvious exposure: five customers generate around 70% of sales, and diagnostics Demand is already softer. Revenue has fallen for two consecutive years, and the company expects Working Capital to absorb a further 100 to 150 basis points of revenue in FY27. The pension recovery plan claims a large slice of cash flow for more than a decade, constraining investment and dividends, and the £36m facility matures in April 2028. Leverage is modest at 1.3 times EBITDA, but the going-concern disclosure flagged a covenant breach in a combined downside case.

Governance history also matters: the FY25 audit overran, forcing a temporary suspension of the shares from 1 August to 1 September 2025, after which the group changed auditor. Currency movements, US Tariff policy and geopolitical uncertainty are further sensitivities for a group operating in the US, Europe, China and India.

Outlook

Carclo has demonstrably rebuilt margins since its 2022 turnaround, and management's tone is confident. Yet with the shares at 35p on 2 September 2026, against a 52-week high of 83.6p last October according to lse.co.uk, the market appears more focused on falling revenue, rising net debt and the pension burden than on profit progress. The AGM statement and FY27 interims will show whether the promised second-half recovery is materialising. Until revenue turns positive and cash conversion recovers, Carclo remains a story of operational improvement in search of top-line confirmation.